Attovia Therapeutics has dosed the first participant in a groundbreaking Phase 1 clinical trial evaluating ATTO-1310, marking the company's transition to a clinical-stage biotechnology organization. The novel therapeutic, designed as a subcutaneous half-life extended (HLE) ATTOBODY-based anti-IL-31 biotherapeutic, targets chronic pruritus, particularly focusing on cases of unknown origin (CPUO).
Clinical Trial Design and Objectives
The Phase 1 study (NCT06787586) employs a rigorous randomized, double-blind, placebo-controlled methodology, incorporating both single-ascending dose and multiple-ascending dose components. Researchers will evaluate the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adult volunteers and patients with pruritic disease.
Addressing an Unmet Medical Need
"Chronic pruritus deeply affects millions of patients in the US and beyond, and there are currently no approved treatments for conditions like CPUO," stated Dr. Hubert Chen, chief medical officer of Attovia. The company is collaborating with international Key Opinion Leaders (KOLs) who have advocated for developing effective treatments for these patients.
ATTO-1310 shows promise in achieving what could be a best-in-disease therapeutic profile, potentially offering:
- Rapid and deep relief from itch
- Favorable safety profile
- Convenient, infrequent subcutaneous dosing regimen
Expanding Pipeline Development
Beyond ATTO-1310, Attovia is advancing several other innovative programs utilizing their ATTOBODY platform:
- ATTO-3712: A first-in-class anti-IL13 x IL31 half-life extended bispecific targeting atopic dermatitis and other inflammatory conditions
- ATTO-004: A multispecific therapeutic under development for inflammatory bowel disease
- Two additional discovery-stage programs with potential applications across multiple diseases
The company's ATTOBODY platform enables the development of first-in-class and best-in-class bispecific and multispecific therapeutics, positioning Attovia at the forefront of innovative treatments for immune-mediated diseases.
